Drug Profile
Research programme: beta-lactam anti-bacterials - VenatoRx Pharmaceuticals
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator VenatoRx Pharmaceuticals
- Class Antibacterials; Beta-lactams
- Mechanism of Action Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Bacterial infections in USA (unspecified route) (VenatoRx Pharmaceuticals pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Bacterial-infections in USA